Quinazoline derivatives
View Patent ↗This disclosure concerns novel quinazoline compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful anticancer agents, especially in inhibiting the function of the EGF receptor tyrosine kinases, HER1 tyrosine kinase, and HER2 tyrosine kinase. Thus, the disclosure also concerns a method of treating hyperproliferative diseases or conditions, such as various cancers and benign prostate hyperplasia (BPH), by use of these novel compounds or a composition comprising such novel compounds.
1. A compound of formula (If) or a pharmaceutically acceptable salt thereof:
wherein
R 1 , R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, deuterium, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, cyano, -L-R 6 , —OR 7 , —C(O)OR 8 , —OC(O)R 9 , —C(O)R 10 , —SR 11 , —S(O) 2 R 12 , —S(O)R 12 , —NR a R b , and —NHC(O)R 13 , wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl each may optionally comprise one or more deuterium atoms;
Y is selected from the group consisting of from hydrogen, deuterium, —OCH 3 , —OCD 3 , —OCD 2 CH 3 , —OCH 2 CD 2 OCH 3 , —OCH 2 CH 2 OCD 3 ,
R x , at each occurrence, is independently hydrogen or deuterium;
R e and R f are each independently hydrogen, deuterium, or C 1 -C 4 alkyl optionally comprising one or more deuterium atoms;
R p and R q are each independently hydrogen or deuterium;
R y and R z are each independently hydrogen or detuerium;
L is C 1 -C 4 alkylene optionally comprising one or more deuterium atoms;
R 6 is selected from hydrogen, deuterium, C 1 -C 4 alkyl, aryl, heteroaryl, cycloalkyl, carbocyclyl, heterocyclyl, —SR 11 , and —OR 7 , wherein said alkyl, aryl, heteroaryl, cycloalkyl, carbocyclyl, and heterocyclyl each may optionally comprise one or more deuterium atoms;
R 7 is hydrogen, deuterium, C 1 -C 6 alkyl, aryl, heteroaryl, cycloalkyl, carbocyclyl, heterocyclyl, or -L 5 -R 20 , wherein said alkyl, aryl, heteroaryl, cycloalkyl, carbocyclyl, and heterocyclyl each may optionally comprise one or more deuterium atoms;
R 8 is hydrogen, deuterium, C 1 -C 6 alkyl, or benzyl, wherein said alkyl and benzyl each may optionally comprise one or more deuterium atoms;
R 9 is hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, or heteroaryl, wherein said alkyl, cycloalkyl, aryl, and heteroaryl each may optionally comprise one or more deuterium atoms;
R 10 is hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, or heteroaryl, wherein said alkyl, cycloalkyl, aryl, and heteroaryl each may optionally comprise one or more deuterium atoms;
R 11 is hydrogen, deuterium, C 1 -C 6 alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl each may optionally comprise one or more deuterium atoms;
R 12 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, heteroaryl, or NR c R d , wherein said alkyl, cycloalkyl, aryl, and heteroaryl each may optionally comprise one or more deuterium atoms;
R 13 is C 3 -C 6 cycloalkyl optionally substituted by one or more substituents independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, oxo, or —C(O)NR c R d and optionally comprising one or more deuterium atoms;
L 5 is methylene or ethylene, each optionally comprising one or more deuterium atoms;
R 20 is aryl or heteroaryl, each optionally comprising one or more deuterium atoms;
R a and R b are independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and benzyl, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, and benzyl each may optionally comprise one or more deuterium atoms;
R c and R d are each independently hydrogen, deuterium, C 1 -C 6 alkyl, benzyl, or aryl wherein said alkyl, aryl, and benzyl each may optionally comprise one or more deuterium atoms; and
wherein any said aryl, heteroaryl, and benzyl each may optionally be substituted with one to five substituents independently selected from C 1 -C 6 alkyl, C 1 -C 4 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 4 haloalkoxy, halogen, hydroxyl, cyano, and nitro;
wherein any said carbocyclyl, cycloalkyl, or heterocyclyl may optionally be substituted with one or more substituents independently selected from C 1 -C 6 alkyl, C 1 -C 4 haloalkyl, C 1 -C 6 alkoxy, halogen, hydroxyl, and oxo;
wherein each said alkyl, haloalkyl, alkoxy, haloalkoxy, and hydroxyl may optionally comprise one or more deuterium atoms; and
wherein at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R x , R e , R f , R P , R q , R y , R z , or Y comprises one or more deuterium atoms.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is selected from hydrogen, deuterium,
3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein Y is
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R e and R f are each independently CH 3 or CD 3 .
5. The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein each of R e and R f is CD 3 .
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from hydrogen, deuterium, F, Cl,
7. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or F.
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 4 are each independently selected from hydrogen, deuterium, F, Cl, —C≡CH, and —C≡CD.
9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein R 2 is Cl or —C≡CH and R 4 is hydrogen.
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 5 are each independently selected from hydrogen, deuterium, and F.
11. The compound of claim 10 or a pharmaceutically acceptable salt thereof, wherein each of R 3 and R 5 is hydrogen.
12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each R x is hydrogen.
13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R P , R q , R y , and R z are each hydrogen.
14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is
(S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(D 6 -dimethylamino)but-2-enamide;
(S,E)-4-(D 6 -dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydro furan-3-yloxy)quinazolin-6-yl)but-2-enamide;
(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-((3-D)-tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; or
(E)-4-(dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(3-D-tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide.
15. A composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
16. The composition of claim 15 , further comprising a second agent.
17. The composition of claim 16 , wherein said second agent is a tyrosine kinase inhibitor.